Dupixent gains FDA approval for expanded use in adolescents with CRSwNP
Regeneron Pharmaceuticals and Sanofi receive FDA approval for Dupixent as add-on treatment for adolescents with CRSwNP, based on Phase 3 trials showing improvements in nasal congestion, polyp size, and sense of smell, and reduced need for corticosteroids or surgery.
Reference News
Dupixent gains FDA approval for expanded use in adolescents with CRSwNP
Regeneron Pharmaceuticals and Sanofi receive FDA approval for Dupixent as add-on treatment for adolescents with CRSwNP, based on Phase 3 trials showing improvements in nasal congestion, polyp size, and sense of smell, and reduced need for corticosteroids or surgery.